Monday, August 31, 2026

Moderna Stock Bearish Momentum With A 3% Drop At Session Start On Thursday

ViaNews Editorial Team

December 24, 2020

Moderna Stock Bearish Momentum With A 3% Drop At Session Start On Thursday

Shares of Moderna dropped 3.27% to $126.08 at 09:36 EST on Thursday, after three consecutive sessions in a row of losses. NASDAQ Composite is dropping 0.29% to $12,771.10, following last session's downward trend, This seems, at the moment, a somewhat negative trend trading session today.

Moderna's last close was $125.88, 41.58% under its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1841.7% for the ongoing quarter and 19117.5% for the next. The company's growth estimates for the ongoing quarter is a negative 2.7% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $126.08 at 09:36 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's worth is higher than its 50-day moving average of $118.15 and way higher than its 200-day moving average of $81.36.

Previous days news about Moderna

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

Moderna, biontech post worst day for vaccine stocks in a month. According to Bloomberg Quint on Tue Dec 22, "Tuesday's slide puts a small dent in a rally that has pushed Moderna's shares to jump more than sixfold so far this year while BioNTech has nearly tripled in value.", "The leading U.S. Covid-19 vaccine makers sank on Tuesday as Moderna slumped 11% and BioNTech fell almost 10%. "

Health Canada authorizes Moderna Covid-19 vaccine. According to Business Insider on Wed Dec 23, "Moderna is currently conducting additional studies in children from 12 years of age and older, and this indication could be revised in the future to include children if the data from these studies support it.", "The different storage and handling requirements of the Moderna COVID-19 vaccine mean that it can be distributed to isolated and remote communities, including the territories."

Moderna shot gets approval in Canada’s expanding vaccine effort. According to Bloomberg Quint on Wed Dec 23, ""The different storage and handling requirements of the Moderna Covid-19 vaccine mean that it can be distributed to isolated and remote communities, including the territories."", "Canada's public health authorities approved Moderna Inc.'s coronavirus vaccine, the second shot to be licensed in a country that's secured more doses per person than any other around the world."

Canada authorizes Moderna vaccine. According to MarketWatch on Wed Dec 23, "Shares of Moderna Inc. were down 0.1% in trading on Wednesday after it said Canada authorized its COVID-19 vaccine for adults. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com